Fig. 5
FAK inhibitor decreased collagen deposition and inhibited CAF activation. A Diagram depicting treated time schedule with FAK inhibitors for the subcutaneous KL tumor model. B IHC staining for p-FAK in KL tumors treated with FAK inhibitor at different time points (Day 3, 7,14). Scale bars, 200 μm. C GO analysis for significantly downregulated genes in KL tumors treated with FAK inhibitors at Day14 compared to control (left) and treated with FAK inhibitors at Day14 compared to Day7. Representative IHC or immunofluorescent staining and quantification of D Collagen I, scale bars, 200 μm. E Collagen III, scale bars, 200 μm. F FAP, scale bars, 50 μm. G α-SMA, scale bars, 50 μm, in KL tumors treated with FAK inhibitor at different time points (Day 3, 7,14). Red, FAP staining; green, α-SMA staining; blue, DAPI staining. Unpaired Student’s t-test was performed and results in each group were presented as mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001, and nsp-values with no statistical difference. KL, KRASG12DLKB1−/−; CAF, cancer-associated fibroblast; FAK, focal adhesion kinase; FAP, fibroblast activation protein; SMA, smooth muscle actin; IHC, immunohistochemistry; BP, biological process; CC, cellular component; MF, molecular function; SEM, standard error of mean